SUBSCRIBE
SUBSCRIBE

Ellen Bombela

Steve Worland/courtesy of eFFECTOR
Drug Development
MacroGenics’ Breast Cancer Treatment Disappoints in Phase III
The biopharmaceutical company announced the final overall survival analysis of its drug MARGENZA in SOPHIA Phase III study in adults with metastatic breast cancer.
September 8, 2021
 · 
2 min read
 · 
Ellen Bombela
Business
Ginkgo’s Momentum Continues with Latest String of Collaboration Announcements
Boston-based Ginkgo Bioworks has been having a banner year and doesn’t show any signs of stopping with its recent string of collaboration announcements.
September 7, 2021
 · 
2 min read
 · 
Ellen Bombela
Business
Meet the World’s Top Life Sciences Billionaires
The life sciences industry was well-represented, with a handful of names featured in the top 100.
September 2, 2021
 · 
2 min read
 · 
Ellen Bombela
Deals
VectivBio Expands Rare Disease Pipeline with Comet Therapeutics Acquisition
Adding to its list of achievements, on Tuesday the Swiss biotech announced it is acquiring Comet Therapeutics.
September 1, 2021
 · 
2 min read
 · 
Ellen Bombela
Business
Lilly and Lycia Ink Collaboration and Licensing Deal Worth Up to $1.6 Billion
Lycia will be receiving a $35 million upfront payment from Lilly and is eligible for over $1.6 billion in potential milestone payments.
August 26, 2021
 · 
2 min read
 · 
Ellen Bombela
Maxigesic IV on hold until FDA gets clarity on the
Policy
CDC: Unvaccinated People are 29 Times More Likely to Be Hospitalized for COVID-19
The report also highlighted that an unvaccinated individual is five times more likely to get COVID-19 than someone who is fully vaccinated.
August 24, 2021
 · 
2 min read
 · 
Ellen Bombela
Deals
Working to Tackle Drug Resistance in Oncology Patients, Tyra Aims for $100 Million IPO
Tyra Biosciences aspires to raise a $100 million IPO, according to its S-1 form filed with the U.S. Securities and Exchange commission late last week.
August 24, 2021
 · 
2 min read
 · 
Ellen Bombela
Business
Life Sciences Companies Expand Their Footprints in the US and Canada
August has been busy with a flurry of life sciences expansion announcements, particularly in the United States and Canada. Here’s a look at a few companies increasing their presence in the two countries.
August 18, 2021
 · 
2 min read
 · 
Ellen Bombela
Chip Somodevilla/Getty Images
Business
Former Medivation Exec Charged with Insider Trading Ahead of 2016 Pfizer Acquisition
The latest biopharma insider trading scandal stems from Pfizer’s acquisition of Medivation in 2016.
August 17, 2021
 · 
2 min read
 · 
Ellen Bombela
Courtesy Getty Images
3 Simple Ways to Succeed in a Hybrid Work Environment
If you are in a hybrid work environment, you might be finding it difficult to work between office and home. Here are a few tips to help optimize your work.
August 16, 2021
 · 
2 min read
 · 
Ellen Bombela
Drug Development
Reify Health Raises $220 Million to Speed Up Clinical Trials and Get Meds to Patients Faster
Trying to get clinical trials enrolled and completed creates a bottleneck that has hindered drug development for years. With a fresh $220 million in hand, Reify Health is looking to change that.
August 11, 2021
 · 
2 min read
 · 
Ellen Bombela
Business
CEO Steps Down as Epizyme Finalizes 5-Year Growth Strategy
The Cambridge, Mass.-based company announced that industry veteran Grant Bogle has taken over as president and CEO.
August 10, 2021
 · 
2 min read
 · 
Ellen Bombela
BioForest
Sonoma Scores $265 Million to Restore Immune System Balance
Sonoma BioTherapeutics continues to work toward its goal of restoring immune system balance through complementary regulatory T cell therapy and effector T cell conditioning, this time with the help of an oversubscribed Series B round.
August 4, 2021
 · 
2 min read
 · 
Ellen Bombela
Deals
Danaher Expands Life Sciences Segment with $9.6 Billion Buy
Global science and technology innovator Danaher Corporation is adding another company to its ever-growing global operation.
June 17, 2021
 · 
2 min read
 · 
Ellen Bombela
Kena Betancur/VIEWpress/Corbis via Getty
Business
Bayer Closes Doors to Mission Bay Site as Company Aims Focus on Other U.S. Locations
This week, the German drug company announced that it is closing the doors to its ‘innovation hub’ in Mission Bay.
June 15, 2021
 · 
2 min read
 · 
Ellen Bombela
Load More